<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002719</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06954</org_study_id>
    <secondary_id>EORTC-06954</secondary_id>
    <secondary_id>ITA-GIMEMA-AML13</secondary_id>
    <nct_id>NCT00002719</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number&#xD;
      of immune cells found in the bone marrow or peripheral blood and may help a person's immune&#xD;
      system recover after chemotherapy and radiation therapy. Combining more than one drug and&#xD;
      giving drugs in different ways may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy&#xD;
      with or without G-CSF in treating older patients with acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the role of granulocyte colony-stimulating factor given during and/or&#xD;
      after remission induction with MICE (mitoxantrone/cytarabine/etoposide) in elderly patients&#xD;
      with acute myelogenous leukemia (AML). II. Compare the complete remission (CR) rate and&#xD;
      survival of these patients when treated with nearly equivalent doses of oral vs. intravenous&#xD;
      mini-ICE (idarubicin/cytarabine/etoposide) as consolidation therapy given on an outpatient&#xD;
      basis. III. Evaluate the feasibility of a second intensive consolidation regimen consisting&#xD;
      of BAVC (carmustine/amsacrine/etoposide/cytarabine) followed by autologous stem cell support&#xD;
      in patients under age 71 who are in CR and have good performance status.&#xD;
&#xD;
      OUTLINE: Randomized study. All patients are randomly assigned to Arms IA through ID for&#xD;
      Induction. Patients who achieve CR and who have adequate organ function and performance&#xD;
      status are then randomly assigned to Arm IIA or IIB for Consolidation. At selected centers,&#xD;
      patients in CR after their first Consolidation course who are under age 71 and in very good&#xD;
      clinical condition are treated on Regimen A (in lieu of a second Consolidation course). The&#xD;
      following acronyms are used: AMSA Amsacrine, NSC-249992 ARA-C Cytarabine, NSC-63878 BAVC&#xD;
      BCNU/AMSA/VP-16/ARA-C BCNU Carmustine, NSC-409962 DHAD Mitoxantrone, NSC-301739 G-CSF&#xD;
      Granulocyte Colony-Stimulating Factor (Rhone-Poulenc Rorer) IDA Idarubicin, NSC-256439 MICE&#xD;
      DHAD/ARA-C/VP-16 Mini-ICE IDA/ARA-C/VP-16 PBSC Peripheral Blood Stem Cells VP-16 Etoposide,&#xD;
      NSC-141540 INDUCTION: Arm IA: 3-Drug Combination Chemotherapy. MICE. Arm IB: 3-Drug&#xD;
      Combination Chemotherapy plus Hematologic Toxicity Attenuation. MICE; plus G-CSF. G-CSF&#xD;
      during chemotherapy. Arm IC: 3-Drug Combination Chemotherapy plus Hematologic Toxicity&#xD;
      Attenuation. MICE; plus G-CSF. G-CSF after chemotherapy. Arm ID: 3-Drug Combination&#xD;
      Chemotherapy plus Hematologic Toxicity Attenuation. MICE; plus G-CSF. G-CSF during and after&#xD;
      chemotherapy. CONSOLIDATION: Arm IIA: 3-Drug Combination Chemotherapy. Mini-ICE. Intravenous&#xD;
      IDA/VP-16/ARA-C. Arm IIB: 3-Drug Combination Chemotherapy. Mini-ICE. Oral IDA/VP-16 +&#xD;
      subcutaneous ARA-C. Regimen A: Stem Cell Mobilization followed by 4-Drug Combination&#xD;
      Myeloablative Chemotherapy with Stem Cell Rescue. G-CSF; followed by BAVC; with PBSC.&#xD;
&#xD;
      PROJECTED ACCRUAL: 500 patients will be randomized for Induction, of whom an anticipated 238&#xD;
      patients will be randomized for Consolidation. If at interim analyses survival is shorter on&#xD;
      Regimen A, that regimen will be closed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1995</start_date>
  <primary_completion_date type="Actual">November 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Leukemia</condition>
  <condition>Neutropenia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amsacrine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Acute myeloblastic leukemia (AML) At least 30% blast cells in bone&#xD;
        marrow smear Secondary AML eligible, as follows: Secondary to myelodysplastic syndrome (but&#xD;
        not other myeloproliferative diseases) Secondary to cured Hodgkin's disease or other cured&#xD;
        malignancy Secondary to alkylating agents or radiation for other reasons Acute&#xD;
        promyelocytic leukemia (M3) referred to the collaborative Gruppo Italiano Malattie&#xD;
        Ematologiche Maligne dell'Adulto-EORTC protocol (EORTC-06952) No blast crisis of chronic&#xD;
        myeloid leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 61 to 80 Performance status: WHO 0-2 Life expectancy: No&#xD;
        marked impairment from disease other than AML Hematopoietic: Not applicable Hepatic:&#xD;
        Bilirubin less than 2 x ULN Renal: Creatinine less than 2 x ULN Cardiovascular: LVEF at&#xD;
        least 50% No severe cardiac disease Pulmonary: No severe pulmonary disease Other: HIV&#xD;
        seronegative (if tested) No uncontrolled infection No severe neurologic, metabolic, or&#xD;
        psychiatric disease No other concomitant disease that precludes protocol therapy No other&#xD;
        progressive malignant disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: No prior chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roel Willemze, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Mandelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Policlinico Umberto Primo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto Primo</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica. 2007 Mar;92(3):389-96. doi: 10.3324/haematol.10552.</citation>
    <PMID>17339189</PMID>
  </results_reference>
  <results_reference>
    <citation>Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrere F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T; EORTC/GIMEMA Leukemia Group. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005 Jul 1;106(1):27-34. doi: 10.1182/blood-2004-09-3728. Epub 2005 Mar 10.</citation>
    <PMID>15761020</PMID>
  </results_reference>
  <results_reference>
    <citation>Jehn U, Suciu S, Thomas X, Lefrere F, Muus P, Berneman Z, Marie JP, Adamo F, Fillet G, Nobile F, Ricciuti F, Leone G, Rizzoli V, Montanaro M, Beeldens F, Fazi P, Mandelli F, Willemze R, de Witte T, Amadori S. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. Leukemia. 2006 Oct;20(10):1723-30. doi: 10.1038/sj.leu.2404356. Epub 2006 Aug 17.</citation>
    <PMID>16932345</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2004</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>neutropenia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Amsacrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

